Highest-materiality recent filing
Chemours Q1 net loss widens to $29M; adjusted EBITDA up 2% to $169M
Net sales $1.381B, up 1% YoY; TSS segment posted record Q1 with double-digit Opteon growth.
Shareholders approve 2026 Equity Plan, elect 11 directors at annual meeting
2026 Equity Plan approved with ~96.7% of votes cast; authorizes 6,375,275 shares for issuance.
Chemours issues $700M 7.875% senior notes due 2034; refinances 2027 and 2028 notes
Closed private offering of $700M aggregate principal of 7.875% senior notes due 2034.
Chemours Q4 net loss widens to $47M; full year 2026 outlook: Adj. EBITDA $800M-$900M
Q4 net loss $47M (-$0.31/diluted) vs loss $11M (-$0.08) YoY; adjusted net income $7M ($0.05) vs $14M ($0.09).
Chemours agrees to sell Taiwan land for $360M, proceeds to reduce debt
Total gross cash proceeds of approximately $360 million from sale of former TiO2 site in Kuan Yin, Taiwan.
Chemours Q3 net income $60M vs loss prior year; adjusted EBITDA $195M down 3%
Net income of $60M ($0.40/share) reverses prior-year loss of $32M; adjusted net income $30M ($0.20) vs $61M.
Chemours Q2 net loss $381M; adjusted EBITDA up 22% to $253M; NJ PFAS settlement reached
Net loss of $381M ($2.54 diluted EPS) vs net income $60M ($0.39) in Q2 2024; adjusted net income $87M ($0.58).
Chemours, DuPont, Corteva agree to $875M NJ PFAS settlement; Chemours share ~$250M PV
Total $875M cash over 25 years; pre-tax PV ~$500M (8% discount); Chemours 50% (~$250M PV).
Chemours Q1 net loss of $4M vs profit $54M; adjusted EBITDA $166M; cuts dividend
Net loss $4M, diluted EPS -$0.03 vs net income $54M, EPS $0.36 YoY.
Chemours reports Q4 2024 net loss of $8M, provides FY2025 EBITDA guidance of $825-975M
Q4 Net Sales $1.4B flat YoY; Net Loss $8M ($0.05 diluted) vs prior year loss $18M.
Chemours prices $600M 8% senior notes due 2033 to refinance 2026 notes
$600M principal of 8.000% senior unsecured notes due 2033 priced in private offering.
Chemours Q3 net loss $27M on $56M impairment; adjusted EPS $0.40; TSS Opteon sales up 21%
Net loss of $27M ($0.18/diluted share) due to $56M non-cash impairment of APM goodwill.
Chemours Q2 net income $70M vs prior loss; adj EBITDA down 36%
Net sales $1.5B (-6% YoY); net income $70M ($0.46 diluted EPS) vs prior-year net loss $376M ($2.52 loss).
Chemours names Shane Hostetter as CFO effective July 1, 2024
Hostetter joins from Quaker Houghton, where he served as CFO since April 2021.
Paused production at Altamira TiO2 facility in Mexico due to severe regional drought.
Chemours Q1 earnings: net sales $1.35B (-12% YoY), net income $52M, adj EBITDA $193M
Net sales $1.35B, down 12% YoY; volumes -6%, price -5%.
Chemours CFO Lock resigns amid accounting review; gets extended options, no severance
Resigned as SVP & CFO effective April 23, 2024; no severance, no 2023 or 2024 annual incentive.
On March 9, 2025, Guillaume Pepy notified the Board of Directors (the “Board”) of The Chemours Company (the “Company”) of his decision not to seek re-election to the Board at the Company’s 2025 Annual Meeting of Shareholders, when his current term expires.
On February 13, 2025, Curtis V. Anastasio notified the Board of Directors (the "Board") of The Chemours Company (the "Company") of his decision not to seek re-election to the Board at the Company's 2025 Annual Meeting of Stockholders, when his current term expires.
appointed Leslie M. Turner as a member of the Board, effective February 19, 2025.
On January 3, 2025, the Board of Directors (the “Board”) of The Chemours Company (the “Company”) appointed Joseph D. Kava as a member of the Board, effective January 3, 2025.
On July 23, 2024, David A. Will was appointed as Controller and Chief Accounting Officer (principal accounting officer) of The Chemours Company (the “Company”) effective as of August 12, 2024.
On June 12, 2024, the Board of Directors (the “Board”) of The Chemours Company (the “Company”) appointed Livingston “Tony” Satterthwaite as a member of the Board, effective June 12, 2024.
Mr. Hostetter succeeds Matthew Abbott, who has served as the Interim Chief Financial Officer (principal financial and accounting officer) since February 28, 2024. Mr. Abbott will continue serving as the Company’s Senior Vice President & Chief Enterprise Transformation Officer
On May 31, 2024, the Board of Directors (the “Board”) of The Chemours Company (the “Company”) appointed Shane Hostetter as Chief Financial Officer, effective as of July 1, 2024.
On April 23, 2024, Jonathan S. Lock resigned from all positions with The Chemours Company (the “Company”).
Max materiality 0.80 · Median 0.55 · Most common event earnings